Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248195 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(3 months from now) | |
US8840928 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(3 months from now) | |
US10525052 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(3 months from now) | |
US9044398 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Jul, 2023
(3 months from now) | |
US9592200 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(3 months from now) | |
US9763883 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(3 months from now) | |
US10525053 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(3 months from now) | |
US8557291 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar, 2025
(1 year, 11 months from now) | |
US8449909 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(1 year, 11 months from now) | |
US7399488 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar, 2025
(1 year, 11 months from now) | |
US7771707 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(1 year, 11 months from now) | |
US8758813 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jun, 2025
(2 years from now) | |
US9682075 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(7 years from now) | |
US10668060 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(7 years from now) | |
US10004729 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(7 years from now) | |
US10188644 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
US9968598 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
US10646485 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
US9737530 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) |
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
43
United States
5
Japan
3
Canada
3
European Union
1
Slovenia
1
Hungary
1
Lithuania
1
Portugal
1
Denmark
1
Cyprus
1
Spain
1
Australia
1
Poland
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic